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BACKGROUND: Reporting clinically actionable incidental
genetic findings in the course of clinical exome testing is
recommended by the American College of Medical Genet-
ics and Genomics (ACMG). However, the performance of
clinical exome methods for reporting small subsets of genes
has not been previously reported.
METHODS: In this study, 57 exome data sets performed as
clinical (n! 12) or research (n! 45) tests were retrospec-
tively analyzed. Exome sequencing data was examined for
adequacy in the detection of potentially pathogenic variant
locations in the 56 genes described in the ACMG incidental
findings recommendation. All exons of the 56 genes were
examined for adequacy of sequencing coverage. In addition,
nucleotide positions annotated in HGMD (Human Gene
Mutation Database) were examined.
RESULTS: The 56 ACMG genes have 18336 nucleotide
variants annotated in HGMD. None of the 57 exome
data sets possessed a HGMD variant. The clinical exome
test had inadequate coverage for"50% of HGMD vari-
ant locations in 7 genes. Six exons from 6 different genes
had consistent failure across all 3 test methods; these
exons had high GC content (76%–84%).
CONCLUSIONS: The use of clinical exome sequencing
for the interpretation and reporting of subsets of genes
requires recognition of the substantial possibility of
inadequate depth and breadth of sequencing coverage
at clinically relevant locations. Inadequate depth of
coverage may contribute to false-negative clinical ex-
ome results.
© 2014 American Association for Clinical Chemistry
The American College of Medical Genetics and Genom-
ics (ACMG)9 recommends that every clinical exome
test be accompanied with a report on pathogenic find-
ings in 56 genes with well-known clinical importance
(1 ). This controversial guidance (2–7 ) assumes that
the analytical performance of clinical exome sequenc-
ing returns DNA sequence data of sufficient quality to
assess genetic findings that were not validated during
the initial development of the clinical exome test. In
prior studies, the coding sequence not covered by ex-
ome sequencing has ranged from 1.4% to 39.1% (8 –
11 ). The extent of coverage depends on the source of
DNA used for sequencing (saliva, white blood cells),
biochemical characteristics of the targeted region (e.g.,
GC content), methodology of sequence enrichment
(e.g., liquid phase baits), sequencing technology (e.g.,
sequence by synthesis), and basic quality parameters
(e.g., minimum depth of coverage). Moreover, no gen-
eral consensus has been reached regarding the estab-
lishment and reporting of false-negative rates in clini-
cal exome sequencing. Because the ACMG guideline
recommends reporting on pathogenic findings in 56
genes with actionable clinical significance, patients
and physicians may expect that these genes have ade-
quate depth and breadth of sequencing coverage in a
clinical exome analysis. This study surveyed the poten-
tial low sequencing coverage at potentially significant
nucleotide positions that may contribute to false-
negative reporting of pathogenic variants in the 56
ACMG genes.
Materials and Methods
INSTITUTIONAL REVIEW
We obtained human exome sequencing data from sev-
eral sources. Data from Thomas Jefferson University
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and the University of Texas Southwestern Medical
Center were obtained under separate research proto-
cols approved by their respective Institutional Review
Boards.
EXOME CAPTURE METHODS
The TargetSeq (TargetSeq™ Target Enrichment Kit,
Life Technologies), SureSelect v4 (SureSelect™Human
All Exon Target Enrichment System v4#UTR, Agi-
lent Technologies), and TruSeq (TruSeq™ Exome
Enrichment Kit, Illumina) exome capture methods
were optimized before the analysis of the samples in
this study (Table 1). All of the exome capture methods
in this study were solution-phase capture. For TargetSeq
and SureSelect v4, 3 !g genomic DNA was used. For
TruSeq, 1 !g genomic DNA was used.
GENOMIC DNA AND KIT PREPARATION
Genomic DNA was used in each of the exome evalu-
ations (Table 1). The sample type and method of pu-
rification differed for each type of exome evaluation.
Samples for TargetSeq and SureSelect v4 capture were
prepared from genomic DNA extracted from whole
blood extraction kits (QIAamp DNA Midi, Qiagen).
TruSeq exome capture was prepared from genomic
DNA either extracted from whole blood extraction
kits (Gentra Systems Autopure LS, Qiagen) or submit-
ted as purified genomic DNA to a core facility.
SEQUENCING
TargetSeq and SureSelect v4 libraries were sequenced on
a SOLiD 5500xl (Life Technologies). SureSelect v4 ex-
ome sequencing on the SOLiD 5500xl was validated for
clinical use under the US Clinical Laboratory Improve-
ment Amendments; in addition, the laboratory is in-
spected and accredited by the College of American
Pathologists. Illumina TruSeq exome libraries were se-
quenced on a HiSeq 2000 (Illumina) in a research core
facility.
ALIGNMENT AND GENOTYPING
All sequence reads were mapped to the hg19 reference
genome (12 ). We analyzed SOLiD 5500xl sequence
reads with an iterative mapping approach using Ap-
plied Biosystems LifeScope Genomic Analysis Soft-
ware v2.5. Each sequence read was allowed to have a
maximum of 2 mismatches. Illumina HiSeq 2000 se-
quence reads were mapped with the Short Read Map-
ping Package (13 ). The sequence reads were quality-
trimmed with the reads’ associated quality values by
use of Cutadapt (14 ). During mapping, mismatches
(replacements) were allowed that did not comprise
"4% of a given read’s length; no insertions or dele-
tions were permitted. For all sequence mappings, only
those reads mapping uniquely to the human genome
were maintained.
CALCULATION OF COVERAGE OF TARGET REGIONS
We calculated coverage across the exome by intersect-
ing sequence reads with the respective exome capture
kit bed files (targeted regions) using the Bedcov flag in
SamTools (15 ) and the coveragebed module of BED
tools (16 ). Each application identifies the number of
base pairs and number of sequence reads mapping to
each region of the bed file.
We examined targeted exons for adequacy of
breadth of coverage by setting a minimum depth of
coverage at "20$. An exon was considered to have a
low breadth of coverage for a specific exome method if
any base position within the exon of interest had
%20$ depth of coverage in more than half of the
samples examined.
Table 1. Overall performance of exome enrichment methods.
Capture
method
Base pairs
targeted by
method
(megabases) Sequencer
Unique
samples
examined
Mean
uniquely
mapped
reads
(millions)
Mean total
base pairs
generated
(gigabases)
Mean base
pairs
generated
in target
regions
(gigabases)
Mean read
depth in
target
regions
Mean percentage
of targeted coding
nucleotides by
depth of coverage
(%)a
>5× >10× >20×
SureSelect v4
(Agilent)
70 SOLiD 5500xl 12 199 7.6 3.4 120× 95 92 87
TargetSeq
(LifeTech)
37 SOLiD 5500xl 33 206 6.7 2.8 76× 91 89 83
TruSeq
(Illumina)
62 HiSeq 2000 12 92 9.1 4.5 74× 93 91 84
a SureSelect v4 is designed to target 70MB including noncoding regions such as untranslated regions; the analysis for coding nucleotide coveragewas limited to the 50MBof coding
nucleotides targeted by the method.
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We also determined depth of coverage for nucle-
otide positions in the 56 ACMG genes that may be
reported as sites of clinically significant variants.
Single-nucleotide variants (SNVs) that have been re-
ported to occur within the 56 ACMG genes were ex-
tracted from HGMD® (Human Gene Mutation Da-
tabase) Professional 2013.4 (BIOBASE Biological
Databases). The SNVs categorized by HGMD as
“DM” [disease causing (pathological) mutation] were
further analyzed. These DM variants were then used to
create a BED file for the determination of the depth of
coverage.
Results
The exome sequencing data sets examined in the present
study demonstrated the heterogeneity of performance
among various methods (Table 1). TargetSeq and SureSelect
v4 had the highest number of mapped reads, with means
of 206 million and 199 million, respectively. In terms of
base pairs generated in the designed target regions,
SureSelect v4 and TruSeq were the highest, at 7.6 giga-
bases and 9.1 gigabases, respectively. All of the data sets
examined had a mean depth of coverage across all target
regions ranging from 74$ to 120$. The depth of cov-
erage was inversely correlated with the coverage of target
regions. At the low end of stringency ("5$), the lowest
coverage of target regions was 91%; however, with higher
stringency ("20$), the best method covered only 87%
of target regions (SureSelect v4). The SureSelect v4 (clin-
ical method) had 92% of targeted nucleotides covered at
"10$. In comparison, a recent survey of clinical exome
laboratories demonstrates a typical metric of "10$
depth of coverage for 90%–95% of target nucleotides
(17 ).
The 56 genes cited in the ACMG guideline have a
total of 18336 SNVs annotated inHGMDas pathogenic
(DM). None of these HGMDDM variants were identi-
fied in any of the samples examined. The nucleotide po-
sitions of the 18336 HGMD pathogenic sequence vari-
ants were examined for depth of coverage. Although a
recent next generation sequencing laboratory standard
described the use of depth of coverage between 10$ and
20$ at a given nucleotide position (18 ), the present
study used a minimum depth of coverage of "20$ at a
nucleotide position on the basis of studies examining the
depth of coverage necessary for accurate base calling
(8, 10, 11, 19–21).
When the 3 exome methods were compared by
HGMD variant locations, substantial differences were
seen in both design and sequencing coverage (Fig. 1).
The Venn diagram shows the variant locations that were
not in the capture probe designs for the 3 methods exam-
ined. A high number of variant locations were not di-
rectly covered in the capture probe designs of SureSelect,
TargetSeq, and TruSeq (2352, 1779, and 719, respec-
tively) (Fig. 1A). In addition to the variants not covered
in the method design, the number of variant locations
Fig. 1. Overlap of low-coverage HGMD variant positions in 3 exome methods.
The nucleotide positions of 18336 HGMD pathogenic variants in the 56 ACMG genes were examined for absence from the design of 3
exome capture kits (A). In addition, exome sequencing from the 3 kits was examined for low depth of coverage (<20×) of the 18336
HGMD pathogenic variants in at least half of the samples examined for each kit (B). SureSelect (n = 12), TargetSeq (n = 33), TruSeq
(n = 12).
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with low depth of sequencing coverage (%20$) also ex-
amined for SureSelect, TargetSeq, and TruSeq are 842,
1295, and 1269, respectively (Fig. 1B). In the sequencing
results of the 3 methods, low coverage was seen for mul-
tiple variant locations, but the sequencing coverage was
better than the designed capture probe coverage for
SureSelect and TargetSeq. Although the variant locations
may be absent in the designed capture probes, the variant
location may be sequenced if a nearby region has a suc-
cessful capture.
An aggregate analysis of the clinical exome test for
HGMD variant coverage in each of the 56 ACMG genes
was performed (Fig. 2). The heterogeneity of coverage in
terms of the percentage of variants with#10$ or#20$
depth of coverage can be seen for each gene. The clin-
ical exome aggregate data had 4 genes [SDHD (succi-
Fig. 2. Percentage of HGMD variant locations with low depth of coverage.
The2graphs compare thepercentageofHGMDSNV locations coveredby theSureSelect exomemethod (n=12) for eachof the56ACMGgenes. The
yaxis is a list of eachof the56genes. The xaxis is thepercentageof variant locationswith≤10× coverage (left panel) or≤20× coverage (rightpanel).
For each graph, themedian is the boldedhashmarkwithin the rectangle. The left end of the rectangle is the 25th percentile, and the right end of the
rectangle is the75thpercentile. Thewhiskers extend to±1SD fromthemean. Forboth thegene symbols andnamesof thegenesused in this figure,
see the human genes footnote in this article.
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nate dehydrogenase complex, subunit D, integral
membrane protein),10 PMS2 (PMS2 postmeiotic seg-
regation increased 2 [S. cerevisiae]), PCSK9 (propro-
tein convertase subtilisin/kexin type 9), and KCNH2
(potassium voltage-gated channel, subfamily H [eag-
related], member 2)] for which "20% of HGMD
variants had a median inadequate (#20$) depth of
coverage. However, with this aggregate analysis, the
overall percentage of variants in the 56 genes with
inadequate coverage was %10%.
For each exome capture methodology, individual
exons within the ACMG genes were also examined for
consistent adequacy of coverage ("20$) at HGMD
variant positions (Table 2). For example, the gene
ACTC1 (actin, alpha, cardiac muscle 1) had 15 unique
variant locations with low depth of coverage across the 12
samples sequenced by SureSelect; this resulted in 39%
(15/38) of ACTC1 HGMD variant locations having in-
adequate coverage across all 12 SureSelect Samples. By
this analysis, SureSelect had 7 genes [SDHD, TGFBR2
(transforming growth factor, $ receptor II [70/80 kDa]),
GLA (galactosidase, %), SDHC (succinate dehydrogenase
complex, subunit C, integral membrane protein, 15
kDa), COL3A1 (collagen, type III, %1), PMS2, PSCK9]
for which"50% of HGMD variant locations had inad-
equate coverage. TargetSeq and TruSeq had 38 and 9
genes, respectively, with inadequate coverage in "50%
of variant locations. For TargetSeq, 5 genes had"80%of
HGMD variant locations with inadequate coverage.
TruSeq had 4 genes with "80% of HGMD variant lo-
cations with inadequate coverage; 2 of these genes
[SDHAF2 (succinate dehydrogenase complex assembly
factor 2) and GLA] had inadequate coverage at 100% of
HGMD variant locations.
We analyzed exons with inadequate coverage in
more than half the samples examined for each method
(Table 3). Six exons had low coverage in all samples ex-
amined by all methods [APOB (apolipoprotein B) exon
1, KCNH2 exon 13, KCNQ1 (potassium voltage-gated
channel, KQT-like subfamily, member 1) exon 1, RYR1
(ryanodine receptor 1 [skeletal]) exon 90, SCN5A (so-
dium channel, voltage-gated, type V, % subunit) exon 1,
TGFBR1 (transforming growth factor, $ receptor 1)
exon 1]. Many of the exons failed by 1 or 2 methods but
were adequately covered by another method. The gene
with the most exon failures was PMS2 (exons 2, 3, 4, 5,
12, 14, and 15); however, no PMS2 exons with inade-
quate coverage were seen in the TruSeq data set. The
median GC content of all exons with inadequate cover-
age was 65% (range 20%–84%).
Discussion
When the 18336 pathogenic variant positions from 56
genes were examined in aggregate, the clinical exome data
had approximately 90% of variant locations at "20$
depth of coverage (Fig. 2). However, when examined at
the level of individual genes, the paucity of coverage pre-
vented analysis of many variant positions. The clinical
exome tests had 7 genes where "50% of the HGMD
variant locations had inadequate coverage. This inade-
quacy of coverage in a subset of 56 genes from exome
sequencing is due to a combination of factors, including
design of capture probes, high-GC-content targets that
may be difficult to capture and/or sequence, and pseudo-
genes. These factors have been previously discussed in the
context of the overall analytical performance of exome
sequencing (9 ).
The ACMG “incidental findings” guideline recom-
mends that clinical laboratories issue a disclaimer that the
additional 56 clinically important genes examined may
not have the same quality or comprehensiveness as tests
specifically designed to test for these genes. However,
from the perspective of patients and clinicians, the con-
sent or notification of testing for the ACMG 56 genes
may create the false expectation that a sufficient genetic
evaluation of these genes will be performed, regardless of
a laboratory disclaimer. Indeed, the authors of the guide-
line acknowledge that physicians and their patients could
interpret an indeterminate result because of lack of cov-
erage of a clinically important nucleotide position as a
negative result.
The 18336 nucleotide positions used in this study
are an overestimate of the true pathogenic variants in the
56 genes. Variants in the HGMD database have been
shown to be occasionally incorrectly annotated as patho-
genic secondary to errors in the experimental literature or
10 Human genes: SDHD, succinate dehydrogenase complex, subunit D, integral mem-
braneprotein;PMS2,PMS2postmeiotic segregation increased2 (S. cerevisiae);PCSK9,
proprotein convertase subtilisin/kexin type 9; KCNH2, potassium voltage-gated chan-
nel, subfamily H (eag-related), member 2; ACTC1, actin, alpha, cardiac muscle 1;
TGFBR2, transforming growth factor, $ receptor II (70/80 kDa); GLA, galactosidase, %;
SDHC, succinate dehydrogenase complex, subunit C, integral membrane protein, 15
kDa; COL3A1, collagen, type III, %1; SDHAF2, succinate dehydrogenase complex as-
sembly factor 2; APOB, apolipoprotein B; KCNQ1, potassium voltage-gated channel,
KQT-like subfamily, member 1; RYR1, ryanodine receptor 1 (skeletal); SCN5A, sodium
channel, voltage-gated, type V, % subunit; TGFBR1, transforming growth factor, $ re-
ceptor 1;WT1,Wilms tumor 1; VHL, von Hippel-Lindau tumor suppressor, E3 ubiquitin
protein ligase; TSC2, tuberous sclerosis 2; TPM1, tropomyosin 1 (%); TP53, tumor pro-
teinp53; TNNT2, troponin T type2 (cardiac); TNNI3, troponin I type3 (cardiac); TMEM43,
transmembrane protein 43; STK11, serine/threonine kinase 11; SMAD3, SMAD family
member 3; SDHB, succinate dehydrogenase complex, subunit B, iron sulfur (Ip); RYR2,
ryanodine receptor 2 (cardiac); RET, ret proto-oncogene; RB1, retinoblastoma 1; PTEN,
phosphatase and tensin homolog; PRKAG2, protein kinase, AMP-activated, gamma 2
non-catalytic subunit; PKP2, plakophilin 2; NF2, neurofibromin 2 (merlin); MYLK,
myosin light chain kinase;MYL2,myosin, light chain 2, regulatory, cardiac, slow;MYL3,
myosin, light chain 3, alkali; ventricular, skeletal, slow;MYH7,myosin, heavy chain 7,
cardiac muscle, beta;MYH11,myosin, heavy chain 11, smoothmuscle;MYBPC3,myo-
sin binding protein C, cardiac; MUTYH, mutY homolog; MSH2/6, mutS homolog 2/6;
MLH1, mutL homolog 1; MEN1, multiple endocrine neoplasia I; LMNA, lamin A/C;
LDLR, low density lipoprotein receptor; FBN1, fibrillin 1;DSP, desmoplakin;DSG2, des-
moglein 2; DSC2, desmocollin 2; CACNA1S, calcium channel, voltage-dependent, L
type, %1S subunit; BRCA1/2, breast cancer 1/2, early onset; APC, adenomatous poly-
posis coli; ACTA2, actin, alpha 2, smooth muscle, aorta.
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database errors (22 ). Indeed, it was observed in one study
that approximately 80% of the HGMD variants classi-
fied as disease causing have an allele frequency of"5% in
the 1000 Genome Database; by definition, a rare variant
has %5% allele frequency in a population (22 ). How-
ever, the evaluation of depth of coverage at these 18336
variant positions provides a uniform tool for surveying
the quality of exome data sets for reporting on individual
genes. The focus of this study was on adequate depth of
coverage to analyze variants in the context of clinical
testing. However, additional quality metrics need to be
examined in future studies, including the accuracy of
alignment and base calling. A recent study has demon-
strated significant discordance between software pro-
grams that perform alignment and base calling (23 ). In
the prior study, 15 exome data sets were examined by 5
commonly used alignment and variant-calling software
combinations. The SNV concordance between the 5
software combinations was only 57.4%. The indel (inser-
tion or deletion of multiple bases) concordance was only
26.8%. Thus, not only is the exome capture method and
sequencing important, but also the software used for in-
terpretation needs to be carefully evaluated. For clinical
laboratories, much more work needs to be done for stan-
dardizing both capture methods and data analysis. The
ideal validation of clinical exome tests not only should
include aggregate statistics of coverage, but also should
Table 2. HGMD variants with low coverage.
ACMG
genea
HGMD
variants
Unique variant position with
low coverageb
SureSelect TargetSeq TruSeq
ACTC1 38 15 18 12
ACTA2 24 6 4 9
APC 1528 391 397 577
APOB 132 17 42 56
BRCA1 1219 262 321 414
BRCA2 1159 174 582 565
CACNA1S 14 0 6 6
COL3A1 224 122 138 56
DSC2 33 13 21 17
DSG2 50 9 27 14
DSP 89 18 52 23
FBN1 1403 336 547 621
GLA 670 401 397 670
KCNH2 683 237 448 167
KCNQ1 444 52 327 85
LDLR 1445 317 1159 324
LMNA 323 112 252 54
MEN1 567 174 443 110
MLH1 676 281 422 238
MSH2 623 255 273 450
MSH6 236 37 101 0
MUTYH 90 2 77 75
MYBPC3 457 87 366 55
MYH11 12 3 5 1
MYH7 456 149 221 62
MYL2 17 1 10 8
MYL3 16 6 12 5
MYLK 2 0 0 1
NF2 313 133 229 96
PCSK9 34 18 22 2
PKP2 127 42 69 61
PMS2 70 38 32 16
PRKAG2 15 1 4 6
PTEN 405 165 128 29
RB1 595 211 446 386
RET 276 121 219 48
RYR1 410 102 262 107
RYR2 170 34 46 87
SCN5A 624 130 348 174
SDHAF2 3 1 2 3
SDHB 169 69 96 78
SDHC 33 18 17 28
Table 2. Continued.
ACMG
genea
HGMD
variants
Unique variant position with
low coverageb
SureSelect TargetSeq TruSeq
SDHD 122 89 92 9
SMAD3 16 5 14 6
STK11 235 75 197 26
TGFBR1 42 12 9 27
TGFBR2 96 59 63 29
TMEM43 3 0 2 1
TNNI3 59 22 36 5
TNNT2 75 9 39 7
TP53 285 73 178 19
TPM1 33 5 17 15
TSC1 256 86 96 78
TSC2 723 188 565 106
VHL 392 44 299 184
WT1 125 47 81 61
a For both the gene symbols and names of the genes used in this table, see the
human genes footnote in this article.
b Total number of HGMD variant locations with low depth of coverage (<20×) in
every sample for each respective capture kit.
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specifically analyze individual genes and clinically impor-
tant SNVs and indels.
Some experts have advocated that whole genome
sequencing may have fewer quality issues than exome
sequencing, albeit at a much higher resource requirement
for sequencing, data storage, and computational power.
However, a recent study of clinical whole genome se-
quencing reveals that a subset analysis of the 56 ACMG
genes has inadequate coverage for variant detection in
9%–17% of genes (24 ). The concept of deviation from
uniform sequencing coverage has been termed bias, and
each capture method and sequencing technology has dif-
ferences in coverage bias (25 ). This bias is an explanation
for exome samples having good mean or aggregate cov-
erage statistics but poor coverage at specific genes or vari-
ant locations.
Protocol modifications that are well known for
optimization of PCR reactions can be used to de-
crease coverage bias in exome sequencing and other
enrichment-based next generation sequencing technolo-
gies. Previous studies that focused on optimizing exome
sequencing have explored techniques such as changing
DNA polymerase, temperature ramp rate, and denatur-
ation time or adding betaine or tetramethylammonium
chloride (26, 27 ). These modifications have been specif-
ically used to address AT- or GC-rich target regions. In
addition to modifying the reaction conditions or adding
chemical additives, there are successful examples of add-
ing high concentrations of capture probes (spike-in) to
regions with decreased coverage (28, 29 ). In 1 example,
the baseline exome test covered only 75% of 3000 clini-
cally relevant genes (with a requirement for"20$ depth
of coverage at every coding nucleotide); however, with
the addition of a spike-in reagent containing a high con-
centration of probes targeted to low-coverage regions,
97% of 3000 clinically relevant genes had adequate cov-
erage (28 ). These modifications may be used to decrease
coverage bias and improve the overall quality of data
from exome sequencing tests.
The quality of clinical exome sequencing data
should be taken into consideration with the ongoing dis-
cussion on the return of “incidental findings.” Examina-
tion of depth of coverage at specific clinically significant
variant positions as performed by this study may be a
Table 3. Exons with frequent low coverage.a
Gene
(exon) SureSelect TargetSeq TruSeq
GC
content
(%)
Other
observations
APOB (1) 12 33 12 79
BRCA1 (1) 12 33 0 56 Pseudogene
BRCA2 (18) 0 0 8 41
CACNA1S
(18)
0 0 12 56
DSG2 (1) 0 6 12 73 Pseudogene
KCNH2 (1) 4 30 8 65
KCNH2 (2) 7 27 2 75
KCNH2 (4) 5 32 0 69
KCNH2 (12) 6 0 0 66
KCNH2 (13) 12 33 12 78
KCNQ1 (1) 12 33 12 77
LDLR (1) 5 33 12 67
MEN1 (10) 2 24 0 66
MSH6 (1) 11 31 0 72
MYH7 (27) 11 2 0 65
PCSK9 (9) 6 0 0 65
PKP2 (1) 2 23 12 71
PKP2 (6) 6 20 0 58
PMS2 (2) 12 7 0 46
PMS2 (3) 12 6 0 38
PMS2 (4) 5 32 0 46
PMS2 (5) 12 6 0 49
PMS2 (12) 12 6 0 45 Pseudogene
PMS2 (14) 11 6 0 55 Pseudogene
PMS2 (15) 10 0 0 52 Pseudogene
PRKAG2 (5) 0 18 4 72
RB1 (1) 12 33 4 76 Pseudogene
RET (1) 1 27 0 68 Pseudogene
RYR1 (28) 0 16 0 70 Pseudogene
RYR1 (33) 7 5 0 67 Pseudogene
RYR1 (35) 4 0 12 50 Pseudogene
RYR1 (75) 0 0 11 60 Pseudogene
RYR1 (90) 12 33 12 76 Pseudogene
RYR2 (1) 5 32 12 48 Pseudogene
RYR2 (5) 5 25 11 20 Pseudogene,
Repetitive
DNA
RYR2 (6) 0 26 12 36 Pseudogene
RYR2 (82) 0 22 10 57 Pseudogene
RYR2 (93) 0 0 11 36 Pseudogene
SCN5A (1) 12 33 12 81
SCN5A (28) 7 27 0 56
SDHC (2) 0 0 12 54 Pseudogene
SDHC (4) 0 0 11 56 Pseudogene
SDHC (5) 6 6 12 46 Pseudogene
Table 3. Continued.
Gene
(exon) SureSelect TargetSeq TruSeq
GC
content
(%)
Other
observations
SDHD (4) 12 6 0 49
TGFBR1 (1) 12 33 12 84 Pseudogene
TSC2 (34) 0 23 0 67 Pseudogene
VHL (1) 6 14 0 72 Pseudogene
WT1 (1) 7 28 6 73
a Listed are the genes and corresponding exons which had low coverage (<100% of
nucleotides at≥20× depth) inmore than half the samples examined. For both the
gene symbols and names of the genes used in this table, see the human genes
footnote in this article.
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useful routine quality metric for clinical exome/genome
tests. If a clinical laboratory plans to report subsets of
genes from exome data, the target regions of these genes
should be analytically validated before clinical imple-
mentation. In the short term, laboratories should con-
sider supplementing exome methods with assay modifi-
cations or Sanger sequencing to fill in regions with poor
coverage. In the long term, the heterogeneous and occa-
sional poor depth of coverage in this subset of 56 genes
illustrates the opportunity for further innovation in next-
generation sequencing methods.
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